University of Kentucky

UKnowledge
Theses and Dissertations--Medical Sciences

Medical Sciences

2022

TREM2: Gene Expression and Role in Alzheimer’s Disease
Henry Snider
University of Kentucky, henry.snider@uky.edu
Author ORCID Identifier:

https://orcid.org/0000-0003-1399-1256

Digital Object Identifier: https://doi.org/10.13023/etd.2022.312

Right click to open a feedback form in a new tab to let us know how this document benefits you.

Recommended Citation
Snider, Henry, "TREM2: Gene Expression and Role in Alzheimer’s Disease" (2022). Theses and
Dissertations--Medical Sciences. 22.
https://uknowledge.uky.edu/medsci_etds/22

This Master's Thesis is brought to you for free and open access by the Medical Sciences at UKnowledge. It has
been accepted for inclusion in Theses and Dissertations--Medical Sciences by an authorized administrator of
UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.

STUDENT AGREEMENT:
I represent that my thesis or dissertation and abstract are my original work. Proper attribution
has been given to all outside sources. I understand that I am solely responsible for obtaining
any needed copyright permissions. I have obtained needed written permission statement(s)
from the owner(s) of each third-party copyrighted matter to be included in my work, allowing
electronic distribution (if such use is not permitted by the fair use doctrine) which will be
submitted to UKnowledge as Additional File.
I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and
royalty-free license to archive and make accessible my work in whole or in part in all forms of
media, now or hereafter known. I agree that the document mentioned above may be made
available immediately for worldwide access unless an embargo applies.
I retain all other ownership rights to the copyright of my work. I also retain the right to use in
future works (such as articles or books) all or part of my work. I understand that I am free to
register the copyright to my work.
REVIEW, APPROVAL AND ACCEPTANCE
The document mentioned above has been reviewed and accepted by the student’s advisor, on
behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of
the program; we verify that this is the final, approved version of the student’s thesis including all
changes required by the advisory committee. The undersigned agree to abide by the statements
above.
Henry Snider, Student
Dr. Steven Estus, Major Professor
Dr. Melinda Wilson, Director of Graduate Studies

TREM2: Gene Expression and Role in Alzheimer’s Disease

________________________________________
THESIS
________________________________________
A thesis submitted in partial fulfillment of the
requirements for the degree of Master of Medical Science in the
College of Medicine
at the University of Kentucky

By
Henry Coleman Snider
Lexington, Kentucky
Director: Dr. Steven Estus, Professor of Physiology
Lexington, Kentucky
2022

Copyright © [Henry Coleman Snider] [2022]
[https://orcid.org/0000-0003-1399-1256]

ABSTRACT OF THESIS

TREM2: Gene Expression and Role in Alzheimer’s Disease

Genetic mutations in the TREM2 gene are highly correlated with risk of
Alzheimer’s disease, but alternative splicing patterns of TREM2 transcripts have not been
fully described. Characterization of TREM2 alternative splicing will be of significant use
to the scientific community as the field of Alzheimer’s disease research progresses.
The goal of this study was to fully describe splicing patterns in TREM2, as
different splicing isoforms of genes can alter express and/or function of the final protein.
Human blood and anterior cingulate cortex brain tissue from 61 individual donors was
processed and used for PCR and quantitative PCR as well as western blotting in order to
identify and quantify novel TREM2 isoforms.
Previously described transcripts of TREM2 which lacked exons 3 or 4, or which
retained part of intron 3 were replicated in this study. Additionally, we identified a novel
isoform lacking exon 2, D2-TREM2, as well as several novel isoforms lacking multiple
exons. D2-TREM2 mRNA in the brain comprised approximately 10% of total TREM2
RNA in the brain. Quantitative expression of TREM2 and frequency D2-TREM2 were
compared between subjects with and without Alzheimer’s disease, revealing no
significant difference between the two groups. The novel splice isoforms identified in this
study were found across multiple tissue types. D2-TREM2 was found with similar
frequency in non-brain tissues, ranging from 5.3-13.0%. D2-TREM2 was found to be
translated to protein and shares localization and cell trafficking patterns with full-length
TREM2. Both D2-TREM2 and full-length TREM2 are predominantly retained in the
Golgi complex. Additionally, D2-TREM2 was confirmed to be expressed in the brains of
subjects with Alzheimer’s disease as well as those without Alzheimer’s disease.
Exon 2 of TREM2 encodes for the ligand-binding domain, which is essential for
its function as a receptor and thus function of cells on which it is present, such as
microglia in the central nervous system. As D2-TREM2 lacks exon 2, we hypothesize that
D2-TREM2 may inhibit full-length TREM2 function and that targeting TREM2 splicing
may offer a novel therapeutic approach for Alzheimer’s disease.
KEYWORDS: TREM2, Alzheimer’s Disease, Gene Splicing, Gene Expression,
Microglia
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CHAPTER 1. TREM2: BACKGROUND
Abstract
Polymorphisms in the TREM2 gene are considered one of the strongest risk
factors for Alzheimer’s disease. Several mutations have been identified and described but
splicing of the TREM2 gene has not been fully characterized previously. TREM2 splicing
isoforms with exon 3 or 4 skipped or intron 3 retained have been reported, and in this
study, we describe novel isoforms. TREM2 remains a significant topic in the field of
Alzheimer’s disease research, and characterization of TREM2 may prove essential to the
ongoing mission in the medical field of developing treatments for Alzheimer’s disease.
The purpose of this introduction is to provide background information on the genetics of
the TREM2 gene, the physiology of the TREM2 protein, and the role these play as a
mechanism in human disease.
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TREM2 Physiology
TREM2, or triggering receptor expressed on myeloid cells 2, is a protein in the
immunoglobulin family of proteins expressed on myeloid lineage cells including
osteoclasts, microglia, and other phagocytes[1]. The TREM2 protein presents both as a
transmembrane receptor protein and as soluble TREM2 (sTREM2) after proteolytic
cleavage or expression of the transcript lacking the transmembrane domain[2]. The
TREM2 gene contains 5 exons, each coding for a portion of the 230-amino acid fulllength protein. Exon 1 codes for the cell-translocation signal peptide, prompting the cell
to move the full-length protein to the endoplasmic reticulum. Exon 2 codes for an
immunoglobulin-like V-set (IgV) domain, responsible for interaction of TREM2 with
ligands. Exon 3 codes for a short stalk, connecting the IgV domain with the
transmembrane domain, encoded by exon 4. Finally, exon 5 codes for the cytosolic tail of
TREM2[3]. Each exon and its corresponding amino acid sequence is vital for proper
function of full-length TREM2.
In its transmembrane form, TREM2 binds ligands and regulates several crucial
physiological roles, including cell survival and proliferation, phagocytosis, and immune
cell function. TREM2 is of particular significance in its role in the central nervous system
(CNS) via regulation of microglial functions[4]. In particular, TREM2 stimulation in
microglia is a strong activator for phagocytosis. Interestingly, TREM2 can stimulate
phagocytosis in microglia without inducing inflammation via the NF-κB pathway, which
promotes expression of pro-inflammatory cytokine and chemokine genes. This is
contrary to other activators of phagocytosis, such as toll-like receptors (TLRs), which are
often strong activators of the NF-κB pathway. Experimentally, overexpression of TREM2
2

in microglia has been shown to induce phagocytosis of apoptotic neurons while
simultaneously reducing transcription of pro-inflammatory cytokines such as IL-1β and
TNF-α[5].
TREM2 signaling is transmitted primarily through the DAP12 co-receptor signaling
subunit, while also displaying interactions with DAP10. When TREM2 binds a ligand,
TREM2 and DAP12 interact in the membrane via oppositely charged residues. Upon
initiation of this interaction, DAP12 cytosolic residues in its Immunoreceptor TyrosineBased Activation Motifs (ITAMs) are phosphorylated and facilitate intracellular
transduction of the TREM2 signal[6]. This interaction of TREM2 with DAP12 results in
mobilization of calcium, activation of protein kinases, and remodeling of actin[7].

TREM2 in Human Disease
Nasu-Hakola Disease
Polymorphisms in the TREM2 gene are strongly associated with several human
diseases. One of the first diseases implicating TREM2 mutations as a cause is polycystic
lipomembranous osteodysplasia with sclerosing leukoencephalopathy, also known as
PLOSL or Nasu-Hakola disease. Nasu-Hakola disease presents as early-onset dementia
associated with microglial dysfunction and presence of bone cysts due to chronic
dysfunction of osteoclasts, a key cell type in the bone which mediates bone
remodeling[8]. The polymorphisms in TREM2 associated with Nasu-Hakola disease
include missense mutations, which are changes in a single base pair within a codon,
changing the amino acid which is formed during translation of the transcript. The specific
mutations for Nasu-Hakola disease include Y38C, W50C, T66M, and V126G. These
3

deviations from normal the normal TREM2 gene alter the structure of the final TREM2
protein, causing steric issues and disrupting normal ligand binding. Dysfunction of the
TREM2 protein due to these mutations prevents normal functioning of microglia and
osteoclasts, resulting in characteristic Nasu-Hakola disease pathology[9].
Alzheimer’s Disease
TREM2 mutations have also been implicated as a risk factor for Alzheimer’s disease
as well as contribution to the severity of the disease. As TREM2 is a key receptor in
mediating microglial phagocytosis, mutations in the TREM2 gene are associated with
reduced ability to clear neuronal debris, including beta-amyloid (Aβ). This leads to buildup of Aβ, resulting in formation of Aβ “plaques”, a key feature of Alzheimer’s disease
pathology[10]. Genome-wide association studies indicate that a particular TREM2
mutation, R47H, increases late-onset Alzheimer’s disease risk by 3-fold[11]. A 3-fold
risk increase is similar to the risk of the apolipoprotein E (APOE) ε4 allele, a heavily
implicated and widely studied Alzheimer’s disease risk factor. The R47H mutation,
similar to the mutations implicated in Nasu-Hakola disease, is proposed to disrupt normal
ligand binding in TREM2, preventing activation and proper function of microglia in the
CNS, including the aforementioned clearance of Aβ. In cell culture, the R47H mutation
has been shown to disrupt proper cell surface expression of TREM2 and modify
expression of other genes regulating immunity and proliferation. These effects
overlapped significantly with TREM2 knockout cells in culture, providing further
evidence of the disruptive nature of the mutation[12]. Since the discovery of the R47H
mutation and its role as a risk factor for Alzheimer’s disease, a variety of other mutations
in the TREM2 gene have been discovered. The effects of many of these mutations remain
4

unknown. However, some mutations, such as R62H and rs7759295, have been found in
subjects displaying significant Alzheimer’s disease pathology[13]. Alternative splicing of
TREM2 has also been reported, focusing on specific splicing isoforms. While the
majority of Alzheimer’s disease-associated TREM2 mutations are found on exon 2 of the
TREM2 gene, others have been found on exons 3 and 4 as well, and more may yet be
undiscovered[14]. This led us to further investigate TREM2 splicing patterns and seek to
fully characterize splicing variations in the TREM2 gene.
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CHAPTER 2. MATERIALS AND METHODS
Characteristics and Preparation of Samples
Samples of blood and anterior cingulate cortex autopsy tissue from 61 donors were
obtained from the University of Kentucky’s Sanders-Brown Alzheimer’s Disease Center.
The characteristics and cDNA synthesis strategies for these samples have been previously
described[15]. All research methodology was conducted under protocol number 48095 of
the University of Kentucky Institutional Review Board. The samples obtained included
both individuals with confirmed Alzheimer’s disease pathology and individuals with no
significant Alzheimer’s disease pathology. Alzheimer’s disease blood and tissue samples
were from individuals aged 81.7 ± 6.2 years, while non-Alzheimer’s disease samples were
obtained from individuals aged 82.4 ± 8.7 years. Postmortem interval was 3.4 ± 0.6 hours
for Alzheimer’s disease subjects and 2.8 ± 8 hours for non-Alzheimer’s disease subjects.
Alzheimer’s disease subjects were 55% female and 45% male, while non-Alzheimer’s
disease subjects were 46% female and 54% male. Previous (premortem) Mini-Mental State
Exams were conducted on patients, and average scores were 11.9 ± 8 for Alzheimer’s
disease subjects and 28.4 ± 1.6 for non-Alzheimer’s disease subjects. RNA samples were
prepared using Qiagen RNeasy Lipid Tissue Mini Kits (Qiagen #74804) according to
included protocols. Reverse transcription of RNA into cDNA was conducted using
SuperScript IV (Invitrogen #18091050) according to included protocols. For the crosstissue TREM2 splicing analysis, fetal RNA from the various tissue types were obtained
from Stratagene and cDNA preparation methods have been previously described[16].
Protein homogenate was obtained from hippocampal tissue of three Alzheimer’s disease
and three non-Alzheimer’s disease subjects. Approximately 100mg of tissue was added to
6

sucrose buffer: 0.25M sucrose, 20mM EDTA, 20mM EGTA, 100mM Tris, pH of 7.4. The
tissue was then homogenized with pestle in a microcentrifuge tube. One volume of 2X
RIPA buffer (300mM NaCl, 2% NP-40, 2% w/v deoxycholate, 0.2% sodium dodecyl
sulfate, 50mM Tris-HCl, pH of 7.4) was added to homogenized samples. Sucrose and RIPA
buffers contained a final concentration of protease and phosphatase cocktails of 1X.

Cell Culture
HMC3 human microglial cell line was obtained from American Type Culture
Collection (ATCC CRL-3304). Both HEK293 and HMC3 cells were maintained in Eagle’s
Modified Minimum Essential Medium, ATCC modification (ATCC 30-2003) with 10%
fetal bovine serum defined (HyClone, GE Healthcare SH30070.03); 50U/mL penicillin,
50μg/mL streptomycin (Gibco 22400-089). Cells were grown at 37°C in 5% CO2 and air
atmosphere.

TREM2 Splice Isoform Identification: PCR and Sequencing
cDNA samples obtained from anterior cingulate cortex were amplified using TREM2
exon 1 primers (5’-CCTGACATGCCTGATCCTCT-3’) and exon 5 primers (5’GTGTTCTTACCACCTCCCC-3’) using Q5 high-fidelity hot-start polymerase (NEB
#M0493L). Parameters for PCR thermocycling were as follows: 98°C 30 s; 98°C 5 s, 67°C
5 s, 72°C 45 s, 30 cycles; 72°C 2 min, 25°C hold. PCR products were run on 8% acrylamide
gel and subsequently imaged on a BioRad ChemiDoc XR imager. Bands were extracted
from these gels for amplification, using the same settings as above, and purified with
Monarch PCR Cleanup Kits (NEB #T1030L). Purified PCR products were sequenced by
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ACGT (Wheeling, IL) and compared to reference transcript NM_018965.4 to identify
splicing patterns.

TREM2 Transcript Quantification
Quantitative PCR was used to quantify expression of TREM2 transcripts. Primers
corresponding to sequences within exons 1 and 2 were used for expression quantification
of TREM2 exon 2 (forward, 5’-CCTTGGCTGGGGAAGGG-3’; reverse, 5’GGGCATCCTCGAAGCTCT-3’) along with primers corresponding to exon 1-3 junction
and within exon 3 to ultimately quantify the TREM2 exon 2 skipped (D2-TREM2)
isoform (forward, 5’-TTACTCTTTGTCACAGACCC-3’; reverse, 5’GGGCATCCTCGAAGCTCT-3’). PCR was performed using initial 2 min incubation at
95°, followed by 40 cycles of 10 s at 95°C, 20 s at 60°C, and 20 s at 72°C. 20μL
reactions contained 1μM of each primer, 1X PerfeCTa SYBR Green Super Mix (Quanta
Biosciences), as well as 20ng cDNA. Samples were amplified in parallel using serially
diluted standard generated by PCR of cDNA with indicated primers and subsequently
purified and quantified by UV absorbance. Sample results were compared to standard
curve to determine number of copies per sample. Overall TREM2 expression was sum of
copy numbers of TREM2 exon 2 present and exon 2 skipped. All assays were performed
in duplicate and normalized to Iba1 expression as the housekeeping gene. Iba1 was used
due to the fact that CNS TREM2 is expressed exclusively in microglia. For cross-tissue
fetal cDNA comparisons, percent exon 2 skipping was calculated by dividing exon 2
skipped copies by sum of exon 2 skipped and mean exon 2 present copies. Cross-tissue
comparison utilized six technical replicates.
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TREM2 Transcript Cloning
TREM-2 and D2-TREM2 cDNA transcripts for immunofluorescence experiments
were amplified using PCR with primers corresponding to DNA sequences within exons 1
and 5, as above. For D2-TREM2 size standard used for Western Blot, D2-TREM2
transcripts were cloned with the aforementioned exon 1 primers and reverse primer
corresponding to DNA sequence in the 3’ untranslated region (5’CCAGCTAAATATGACAGTCTTGGA-3’) in order to preclude an epitope tag. For PCR
amplification, Platinum Taq (Invitrogen #10966034) was used with the following cycle
parameters: 2 min at 94°C; 30 sec at 60°C, 2 min at 72°C (30 cycles), 7 min at 72°C,
25°C hold. For cloning, pcDNA 3.1-V5/His TOPO-TA cloning kit (Invitrogen
#K480001) was used according to the included protocol. Clones were sequenced for
verification by ACGT (Wheeling, IL) and grown at midi-scale production and
purification with Qiagen Plasmid Plus Midiprep kits (Qiagen #12943).

Transfection of HMC3 and HEK293 Cells
Transfection of HMC3 human microglia and/or HEK293 cells was performed using
Lipofectamine 3000 with Plus reagent (Invitrogen #L3000001) according to included
protocols. Quantities used were: 0.8μL Lipofectamine, 1μL Plus reagent, 250ng plasmid
per well in 8 well glass chamber slides (MatTek CCS-8). All cells were incubated for 24
hours, then HMC3 cells were processed for microscopy and HEK293 cells were
processed for Western Blot.

9

Confocal Immunofluorescence Microscopy
HMC3 cells, after transfection, were fixed using 10% neutral buffered formalin
(Fisher Scientific SF100-4) for 30 minutes and then blocked and permeabilized for 30
minutes using 10% goat serum (Sigma S26-LITER), 0.1% Triton X-100 (Fisher
Scientific BP151-500) in PBS (Fisher BioReagents BP665-1). Primary and secondary
antibodies were diluted in the above blocking and permeabilization buffers, then
incubated at room temperature for 90 minutes. Cells were washed three times in the
above blocking and permeabilization buffers in between primary and secondary antibody
treatment, then three times in the above PBS prior to slide mounting with Prolong Glass
using NucBlue mounting media (Invitrogen #P36981) and high-tolerance No. 1.5 cover
glass (ThorLabs CG15KH1). Imaging was performed using a Nikon A1R HD inverted
confocal microscope with 60X oil objective lens and NIS Elements AR software.

Western Blot
Protein quantification was performed using a Pierce 660 assay (Invitrogen
#1861426) and 40μg loaded per well on 10-20% Tricine gel (Invitrogen #EC6625BOX)
then transferred to a 0.22μm PVDF membrane. This membrane was blotted overnight
with antibody against sequence within the TREM2 cytosolic domain (Cell Signaling
#91068) and probed with goat and anti-rabbit secondary antibody AlexaFluor 800
(Invitrogen #A32735).
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Statistical Analysis
Statistical analyses were performed using GraphPad Prism 8.4.2 software.
Quantitative data were checked for normality by the D’Agostino & Pearson test. The
normally distributed data were analyzed using Welch’s t-test, and data not normally
distributed were analyzed using a two-tailed Mann Whitney test[17].
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CHAPTER 3. ANALYSIS OF TREM2 SPLICING AND EXPRESSION
TREM2 Alternative Splicing in the Human Brain
TREM2 cDNA from anterior cingulate cortex was PCR-amplified with primers
corresponding to sequence within exons 1 and 5. A gene map of TREM2 is shown in
Figure 1 (top), displaying introns and exons of the gene. Significant alternative splicing
was found in the brains of both Alzheimer’s disease and non-Alzheimer’s disease
individuals, shown on acrylamide gel in Figure 1. Each splicing isoform was identified
and sequenced directly to confirm the nature of alternative splices. This study identified
several novel splicing isoforms of TREM2, including isoforms with single exons skipped,
multiple exons skipped, and intron sequence retained.
The study suggested that the TREM2 isoform with exon 2 skipped (D2-TREM2) was
the most abundant alternative splicing isoform. Thus, TREM2 and D2-TREM2 were
quantified in an assay using multiple brain samples. The number of copies of TREM2 was
normalized to AIF1 (allograft inflammatory factor 1), a protein highly expressed in
microglia, where TREM2 is exclusively found in the CNS. The study suggests that total
TREM2 expression does not differ significantly between Alzheimer’s disease and nonAlzheimer’s disease individuals. However, in high-pathology vs. low-pathology
Alzheimer’s disease brains, TREM2 expression appears to increase significantly with
pathology (shown in Figure 2B; p = 0.0014, Welch’s t-test). D2-TREM2 expression was
also investigated with respect to Alzheimer’s disease status. D2-TREM2 expression was
found to be correlated with total TREM2 expression (shown in Figure 2C), but no
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significant difference was observed in D2-TREM2 expression between Alzheimer’s
disease and non-Alzheimer’s disease individuals.

Analysis of TREM2 Alternative Splicing Across Tissue Types
Fetal cDNA libraries from several tissues; aorta, lung, kidney, heart, skeletal muscle,
brain, and liver; were PCR amplified using primers from TREM2 exons 1 and 5 to
determine if TREM2 alternative splicing occurs across tissue types. Each splicing isoform
was observed in the study, despite individual tissues not all containing every isoform
(Figure 3). Quantitatively, a high abundance of the isoform lacking exons 2 and 3 as well
as the isoform lacking exons 2 and 4 were observed. It is worth noting that shorter DNA
fragments are amplified more efficiency and thus PCR may have biased this result. D2TREM2 was abundant across all tissue types, similar to the findings in the adult brains.
D2-TREM2 frequency was similar across each tissue type (Figure 4).

Analysis of D2-TREM2 Localization
D2-TREM2 and full-length TREM2 were cloned into expression vectors and
transfected into HMC3 human microglial cells. Confocal microscopy was used to
determine if D2-TREM2 is trafficked and localized in the same manner as full-length
TREM2. Staining patterns were similar between full-length TREM2 (shown in Figure
5A) and D2-TREM2 (shown in Figure 5B). The pattern of staining has been previously
reported, and the assay performed in this study showed consistent results[18]. Thus, D2TREM2 and full-length TREM2 appear to localize in the same manner. Both D2-TREM2
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and full-length TREM2 are primarily retained in the Golgi complex (D2-TREM2 shown
in Figure 5C, full-length TREM2 shown in Figure 5D).

D2-TREM2 Protein in Human Hippocampus Samples
Hippocampal protein from Alzheimer’s disease and non-Alzheimer’s disease
samples was subjected to Western blotting using antibody against the cytosolic tail of
TREM2 (also present in D2-TREM2), shown in Figure 6. This assay was performed in
order to determine if the D2-TREM2 protein is present in the human brain. Short
exposure time of the blot (shown in Figure 6A) revealed proteins labeled by TREM2
antibody in transfected cells but not in non-transfected cells. This confirms that the bands
on the Western blot are products of D2-TREM2. Long exposure of the blot (shown in
Figure 6B) displays a doublet of bands at 12 and 13 kDa, matching the pattern of D2TREM2 transfected cells. The carboxyl-terminal fragment of TREM2 has a predicted
molecular weight of 8 kDa and the predicted molecular weight of D2-TREM2 is 11 kDa.
Based on this information, both carboxy-terminal fragments and D2-TREM2 migrate at a
higher molecular weight than predicted, by 3 kDa. It can be concluded, based on the
assay performed, that D2-TREM2 protein is present in both Alzheimer’s disease and nonAlzheimer’s disease brains.

14

Figure 1. Extensive Alternative Splicing of TREM2.
TREM2 undergoes significant alternative splicing. A diagram of the TREM2 gene and its
corresponding role in the mature protein is shown. Several novel splicing isoforms were
identified, skipping one or more exons (numbered 1 through 5), or retaining part of an
intron. cDNA from Alzheimer’s disease subjects was compared to non-Alzheimer’s
disease subjects. Exons shown in grey (right) represent sequence after a frameshift
mutation.

Reprinted from Journal of Alzheimer’s Disease, Vol 87 Issue 4, Shaw et al., An Alternatively Spliced TREM2 Isoform Lacking the
Ligand Binding Domain is Expressed in Human Brain, Page No. 1650, Copyright 2022, with permission from IOS Press.
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Figure 2. Quantification of TREM2 and D2-TREM2 in Human Brain Tissue.
qPCR was used to quantify TREM2 transcripts. TREM2 is normalized to AIF1 (expressed
on microglia) to compare copy number of TREM2 in Alzheimer’s disease vs. nonAlzheimer’s disease subjects (A). TREM2 expression is compared between lowpathology and high-pathology subjects (B), p = 0.0014, Welch’s t-test. Number of D2TREM2 copies and full-length TREM2 copies is compared between Alzheimer’s disease
and non-Alzheimer’s disease subjects (C). The percent of total TREM2 copies that were
D2-TREM2 copies were compared between AD non non-AD subjects(D).

Reprinted from Journal of Alzheimer’s Disease, Vol 87 Issue 4, Shaw et al., An Alternatively Spliced TREM2 Isoform Lacking the
Ligand Binding Domain is Expressed in Human Brain, Page No. 1651, Copyright 2022, with permission from IOS Press.
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Figure 3. TREM2 Alternative Splicing Patterns are Present Across Tissue Types.
cDNA from fetal aorta, lung, kidney, heart, skeletal muscle, brain, and liver were
analyzed for TREM2 splicing. The splicing isoforms found in adult human brain tissue
were present across tissues.

Reprinted from Journal of Alzheimer’s Disease, Vol 87 Issue 4, Shaw et al., An Alternatively Spliced TREM2 Isoform Lacking the
Ligand Binding Domain is Expressed in Human Brain, Page No. 1652, Copyright 2022, with permission from IOS Press.
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Figure 4. Quantification of TREM2 and D2-TREM2 Across Tissue Type.
cDNA from multiple fetal tissue types was quantified to investigate percent of D2TREM2 skipped among total TREM2 copies. D2-TREM2 was found to be an abundant
splicing isoform across tissue types. Exon 2 is skipped at a frequency between 5.3-13%.
Data points reflect technical replicates from pooled cDNA libraries.

Reprinted from Journal of Alzheimer’s Disease, Vol 87 Issue 4, Shaw et al., An Alternatively Spliced TREM2 Isoform Lacking the
Ligand Binding Domain is Expressed in Human Brain, Page No. 1652, Copyright 2022, with permission from IOS Press.
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Figure 5. TREM2 and D2-TREM2 Share Localization Patterns.
Transfected HMC3 human microglial cells were analyzed with confocal
immunofluorescence microscopy. Full-length TREM2 (A) and D2-TREM2 (B) exhibit
similar staining patterns. Both D2-TREM2 (C) and full-length TREM2 (D) appear to be
primarily retained in the Golgi complex.

Reprinted from Journal of Alzheimer’s Disease, Vol 87 Issue 4, Shaw et al., An Alternatively Spliced TREM2 Isoform Lacking the
Ligand Binding Domain is Expressed in Human Brain, Page No. 1653, Copyright 2022, with permission from IOS Press.
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Figure 6. Western Blot of Human Brain Indicates Presence of D2-TREM2 Protein.
Western blotting using an antibody tag recognizing the cytosolic tail of TREM2 was
performed. Short exposure (A) shows two proteins labeled by TREM2 antibody in
transfected cells, but not non-transfected cells, confirming presence of D2-TREM2.
Longer exposure (B) shows a doublet of bands at 12 and 13 kDa, matching the pattern in
D2-TREM2 transfected cells. The bands are again present in transfected cells but not nontransfected cells, confirming presence of D2-TREM2.

Reprinted from Journal of Alzheimer’s Disease, Vol 87 Issue 4, Shaw et al., An Alternatively Spliced TREM2 Isoform Lacking the
Ligand Binding Domain is Expressed in Human Brain, Page No. 1654, Copyright 2022, with permission from IOS Press.
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CHAPTER 4. DISCUSSION AND FUTURE DIRECTION
Summary of Findings
The results of this study provide new insights into the splicing patterns of the
TREM2 gene. The findings show that TREM2 undergoes more extensive splicing patterns
than was previously published. Previously available literature has described a number of
alternative splicing isoforms, such as sTREM2 lacking the transmembrane domain, exons
3 and 4 skipped individually, and intron 3 retained, but this study characterized the full
range of TREM2 splicing isoforms in the CNS. The D2-TREM2 splicing isoform has been
reported on recently, providing similar findings to the ones described in this study,
including lack of immunoglobulin domain expression causing a loss of function in the
final protein and similar cell trafficking characteristics to full-length TREM2[19 20]. This
study identifies several novel splicing isoforms of TREM2, shown in Figure 1, which
were not listed on gene library websites such as Ensembl. This provides the scientific
community with a better understanding of the extent to which the TREM2 gene
undergoes alternative splicing and offers a potential basis on which to further investigate
these isoforms.
The study also included investigation of whether a correlation exists between the
common D2-TREM2 splicing isoform and Alzheimer’s disease pathology. Ultimately, it
was determined that there was no significant correlation between frequency of the D2TREM2 isoform and Alzheimer’s disease related pathology. This provides meaningful
insight, as investigation of the TREM2 protein and underlying genetic mechanisms is
considered an important current topic in the field of Alzheimer’s disease research[21].
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While there are still a wide range of questions to be answered regarding the mechanism
behind the involvement of TREM2 in the progression of Alzheimer’s disease pathology,
establishing a strong understanding of the genetic background of TREM2 is paramount.
Localization and cell trafficking patterns of the TREM2 protein were also
investigated in this study. Presence of TREM2 on the cell surface and its receptor activity
have been previously described[22], but localization of splicing isoforms of TREM2 in
comparison to the full-length protein have not been fully characterized. This study
utilized confocal microscopy and immunofluorescent staining in order to determine if
D2-TREM2 localized similarly to full-length TREM2. It was discovered that the D2TREM2 isoform shares highly similar localization with the full-length protein: both were
primarily located in the intracellular Golgi complex (shown in Figure 5C and 5D). Cell
culture experiments indicate that TREM2 exhibits a “feed-forward” mechanism which
elicits cellular activity in response to a stimulus. TREM2 within the transmembrane
Golgi pool is trafficked to the cell surface due to calcium flux[18]. We speculate that D2TREM2 may interfere with this mechanism, as it lacks the immunoglobulin domain
which is vital for signaling that may lead to TREM2 trafficking within the cell.
Western blot also revealed that the D2-TREM2 isoform is present in the human
brain as protein (shown in Figure 6). While the preliminary findings of this study
confirmed that D2-TREM2 mRNA is present and abundant in the human brain, the
presence of the mature D2-TREM2 protein is a novel finding. The correlation between
amount of D2-TREM2 mRNA and protein, when compared to full-length TREM2, is
significantly lower. This may indicate that the D2-TREM2 protein is not readily
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translated as efficiently in the cell, or that the protein itself loses stability when lacking
the amino acid sequence corresponding to exon 2.

Future Direction
TREM2 as a Therapeutic Target
Genetic mutations in the TREM2 gene have been known to be significant risk
factors for Alzheimer’s disease for many years[23]. Certain TREM2 variants have some
of the highest odds-ratios for late-onset Alzheimer’s disease risk, surpassed only by the
APOE4 gene, making it a heavily investigated topic in the field of Alzheimer’s disease
research[24 25]. In particular, the ligand-binding disruption, thought to be a partial lossof-function, caused by the R47H and R62H mutations in TREM2 are considered high-risk
mutations for developing late-onset Alzheimer’s disease[26 27]. We speculate that D2TREM2 is functionally null and thus disrupts normal cell signaling and trafficking when
present on the cell surface, which may lead to complications contributing to generation of
Alzheimer’s disease-related pathology. This would be similar to what has been shown in
studies related to the CD33 gene, which also has a splicing isoform which lacks the
ligand-binding domain[28].
Currently, there is no FDA-approved therapeutic for Alzheimer’s disease
targeting TREM2. There is one ongoing clinical trial targeting TREM2 with monoclonal
antibodies, AL002 (Alector, NCT04592874), which is currently in phase 2 and has
garnered the interest of the scientific community. It is possible that modulation of TREM2
splicing patterns could attenuate onset and progression of Alzheimer’s disease, though
more research into the mechanisms behind TREM2 and its role in the disease will be
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necessary. According to existing literature, the possibility also exists that sTREM2 is
protective for Alzheimer’s disease[29 30]. We report in this study that the TREM2
isoform lacking exon 4 (D4-TREM2) lacks the transmembrane domain, making it likely
to be secreted as sTREM2. This finding, combined with the possibility that sTREM2 is
protective against Alzheimer’s disease, suggests that targeting TREM2 mRNA to enhance
expression of the D4-TREM2 isoform may have potential for therapeutics.
We speculate that the D2-TREM2 isoform may act similarly to R47H and R62H
variants, as D2-TREM2 lacks the immunoglobulin domain, which is essential for
signaling, and the R47H and R62H mutations alter the immunoglobulin domain and
change its function. In vivo studies have shown in mice that targeting TREM2 may serve
to reduce Alzheimer’s disease-related pathology. Targeting TREM2 with monoclonal
antibodies in an R47H mouse model reduced amyloid plaques, neurite dystrophy, and
inflammatory response over time[31]. These results suggest potential for a therapeutic
that may slow the progression of Alzheimer’s disease by targeting TREM2 in patients
with mutations to the gene that increase Alzheimer’s disease risk. Interestingly, TREM2
function as it relates to Alzheimer’s disease appears to change as the disease progresses.
It has been suggested that TREM2 and sTREM2 are beneficial in the early stages of
Alzheimer’s disease progression but exacerbates pathology later in the disease[32].
TREM2 microglial function plays a significant role in the immune inflammatory
response, thus exacerbation of inflammation in later stages of Alzheimer’s disease likely
worsens related pathology. If the role of TREM2 in Alzheimer’s disease indeed changes
over the course of the disease, targeting TREM2 splicing in a patient-specific manner may
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prove to be a valuable therapeutic strategy. A model of a potential way to exploit TREM2
as a therapeutic is shown in Figure 7.
mRNA Therapeutics
Targeting intracellular mRNA with therapeutic drugs has become a prominent
topic of biomedical research. Antisense oligonucleotide (ASO), antisense RNA (asRNA),
short interfering RNA (siRNA), and micro-RNA (miRNA) are blossoming as classes of
drugs that target mRNA sequence in order to interfere with the processes which allow it
to be translated into protein[33]. These drugs are DNA or RNA molecules themselves
and contain sequence complementary to the targeted mRNA. When interacting with the
target mRNA, the drug-mRNA complex effectively prevents gene expression by
preventing translation or via induction of RNase activity which cleaves the doublestranded RNA or DNA-RNA complex[34]. In particular, antisense oligonucleotides have
shown promising results in treating genetic diseases such as spinal muscular atrophy and
age-related macular degeneration.
There is a growing list FDA-approved drugs targeting mRNA in the United
States. One of the most prominent is nusinersen, marketed under the brand name
Spinraza®. Nusinersen is an antisense oligonucleotide used to treat 5q spinal muscular
atrophy (SMA), which is caused by mutations in the survival motor neuron 1 (SMN1)
gene. These mutations prevent the production of functional protein from SMN1
transcripts and leave only the survival motor neuron 2 gene (SMN2, which has a nearidentical sequence to SMN1) to produce the survival motor neuron protein. SMN2 is
expressed at significantly lower rates than SMN1 in healthy individuals due to splicing
differences causing truncation of SMN2 mRNA. Thus, SMN1 protein is produced at
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insufficient levels in individuals with SMN1 mutations, leading to widespread muscle
atrophy which is fatal without treatment. Nusinersen targets SMN2 pre-messenger (presplice) RNA in order to alter splicing and ultimately produce more mature full-length
mRNA which can be translated into survival motor neuron protein[35]. Effectively, this
drug makes up for the lack of protein produced from SMN1 transcripts by increasing the
protein production viability of SMN2 transcripts. Nusinersen significantly increases
quality of life of SMA patients, including positive outcome criteria such as walking
independently and ability to swallow.
While there is currently no FDA-approved drug targeting TREM2 mRNA
transcripts, the potential exists for an oligonucleotide-based therapeutic. Though more
research is necessary to pinpoint if and when splicing variants of TREM2 modulate
Alzheimer’s disease related pathology, antisense oligonucleotide technology could be
used to silence particular variants of the TREM2 transcript. If TREM2 signaling is
protective in early Alzheimer’s disease, decreasing expression of D2-TREM2 may be
beneficial to slow progression of the disease. If TREM2 signaling exacerbates
Alzheimer’s disease pathology later progression, decreasing expression of FL-TREM2
may also slow this stage of progression by limiting the number of functional TREM2
receptors on cells. An example of antisense oligonucleotides accomplishing these goals is
shown in Figure 8.
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Figure 7. Model to Exploit TREM2 Splicing as a Potential Alzheimer’s Disease
Therapeutic.
Early in Alzheimer’s disease, TREM2 signaling may be protective. Thus, decreasing D2TREM2 and increasing full-length TREM2 may be beneficial (left). Conversely, TREM2
may be detrimental later in Alzheimer’s disease, which may make decreasing full-length
TREM2 and increasing D2-TREM2 beneficial by increasing the number of functionally
null receptors (right).

Reprinted from Journal of Alzheimer’s Disease, Vol 87 Issue 4, Shaw et al., An Alternatively Spliced TREM2 Isoform Lacking the
Ligand Binding Domain is Expressed in Human Brain, Page No. 1655, Copyright 2022, with permission from IOS Press.
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Figure 8. Antisense Oligonucleotide Model Targeting FL-TREM2 or D2-TREM2
Model using antisense oligonucleotides to target FL-TREM2 or D2-TREM2. An
oligonucleotide against FL-TREM2 targets sequence at the beginning of exon 2 RNA (A)
in order to reduce FL-TREM2 expression. An oligonucleotide against D2-TREM2 targets
sequence at the exon 1 – exon 3 junction (B), a feature not present in FL-TREM2, in
order to reduce D2-TREM2 expression.

Created with BioRender.com
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